CAMP — Camp4 Therapeutics Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1736730 ·
Last close
$4.00
Market Cap
$251.02M
52W High
$7.75
52W Low
$2.90
ADV30
138,616
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,899,000 | — | -14,029,000 | -28,956,000 | 134,013,000 | 124,522,000 | 26,919,000 |
| Jun 2026 | 1,779,000 | — | -13,380,000 | -33,530,000 | 93,428,000 | 86,398,000 | 94,121,000 |
| Mar 2026 | 1,294,000 | — | -13,071,000 | -18,331,000 | 105,457,000 | 99,209,000 | 74,555,000 |
| Dec 2025 | 348,000 | — | -12,776,000 | -40,284,000 | 117,808,000 | 109,517,000 | 70,104,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,591,000
Investing CF
$-93,000
Financing CF
$76,030,000
CapEx
$-279,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.07
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-344,017,000
Inventory
—
Receivables
$217,000
ST Investments
—
EBIT TTM
$-52,384,000
Pretax Income TTM
$-107,244,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,320,000
EBITDA
$-50,832,000
Free Cash Flow
$-14,889,250
Enterprise Value
$136,710,048
Total Cash
$124,522,000
Total Debt
$6,450,000
Shares Out
62,754,200
Trailing EPS
$-2.11
Book Value
$1.71
ROE
-146.1%
ROA
-29.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,498,000 | -52,061,000 | -80,403,000 | 117,808,000 | 70,104,000 | 47,704,000 | -29,553,000 |
| Dec 2024 | 652,000 | -53,088,000 | -51,791,000 | 78,307,000 | 15,163,000 | 63,144,000 | -45,562,000 |
| Dec 2023 | 350,000 | -51,879,000 | -49,291,000 | 54,946,000 | 178,676,000 | -123,730,000 | -44,155,000 |
| Dec 2022 | 0 | -45,001,000 | -44,192,000 | 102,549,000 | 180,080,000 | -77,531,000 | -38,543,000 |
TTM Snapshot
Revenues TTM
$4,216,000
NetIncome TTM
$-107,244,000
OpCashFlow TTM
—
Assets (Latest)
$93,428,000
Forward EPS
$-0.85
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $250.73M | $0.15 | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $253.10M | $8.69 | — |
| PRE | Prenetics Global Ltd | $248.19M | $16.33 | — |
| QTTB | Q32 Bio Inc. | $258.24M | $8.63 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $242.22M | $6.39 | — |
News headlines (Yahoo Finance, 1h cache)
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-17 21:05 · Yahoo
CAMP4 Therapeutics Targets 2028 for Key SYNGAP1 Trial Data
2026-11-11 09:12 · Yahoo
CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears
2026-11-10 02:14 · Yahoo
CAMP4 Therapeutics Corporation (CAMP) Reports Q3 Loss, Misses Revenue Estimates
2026-11-06 00:00 · Yahoo
CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights
2026-11-05 21:05 · Yahoo
CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
2026-10-29 13:00 · Yahoo
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
2026-10-27 12:00 · Yahoo
CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
2026-10-20 15:04 · Yahoo
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
2026-10-14 12:00 · Yahoo
CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
2026-09-28 19:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.